Non-genomic effects of the androgen receptor and Vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells

Steroids

Volumn 71, Issue 4, 2006, Pages 304-309

  Bonaccorsi, Lorella ^a   Marchiani, Sara ^a   Ferruzzi, Pietro ^a   Muratori, Monica ^a   Crescioli, Clara ^a   Forti, Gianni ^a   Maggi, Mario ^a   Baldi, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Androgen receptor; Invasion; Non genotropic and genomic effects; Steroid receptor

Indexed keywords

ALPHA6BETA4 INTEGRIN; ANDROGEN; ANDROGEN RECEPTOR; BXL 353; BXL 628; EPIDERMAL GROWTH FACTOR RECEPTOR; KERATINOCYTE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ARTICLE; CANCER CELL; CELL INVASION; CONFOCAL MICROSCOPY; DRUG ACTIVITY; DRUG INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOPRECIPITATION; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CALCITRIOL; CELL LINE, TUMOR; GENOMICS; GROWTH INHIBITORS; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; VITAMIN D;

EID: 33645383523     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2005.09.010     Document Type: Article

References (51)

1. H. Grönberg Prostate cancer epidemiology Lancet 361 2003 859 864
2. D.F. Amanatullah, A.T. Reutens, B.T. Zafonte, M. Fu, S. Mani, and R.J. Pestell Cell-cycle dysregulation and the molecular mechanisms of prostate cancer Front Biosci 5 2000 d372 d390
3. P. Koivisto, J. Kononen, C. Palmberg, T. Tammela, E. Hyytinen, and J. Isola Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res 57 1997 314 319
4. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, and C. Palmberg In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 1995 401 406
5. G. Jenster Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines J Pathol 19 2000 227 228
6. M. Marcelli, M. Ittmann, S. Mariani, R. Sutherland, R. Nigam, and L. Murthy Androgen receptor mutations in prostate cancer Cancer Res 60 2000 944 949
7. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, and R. Vessella Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
8. J.T. Isaacs, and W.B. Isaacs Androgen receptor outwits prostate cancer drugs Nat Med 10 2004 26 27
9. Z. Culig, H. Klocker, G. Bartsch, and A. Hobisch Androgen receptors in prostate cancer Endocr Relat Cancer 9 2002 155 170
10. J.D. Debes, and D.J. Tindall Mechanisms of androgen-refractory prostate cancer N Engl J Med 351 2004 1488 1490
11. E. Unni, S. Sun, B. Nan, M.J. McPhaul, B. Cheskis, and M.A. Mancini Changes in androgen receptor nongenotropic signalling correlate with transition of LNCaP cells to androgen independence Cancer Res 64 2004 7156 7168
12. E. Baldi, L. Bonaccorsi, and G. Forti Androgen receptor: good guy or bad guy in prostate cancer invasion? Endocrinology 144 2003 1653 1655
13. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocrine Rev 25 2004 276 308
14. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
15. L. Bonaccorsi, V. Carloni, M. Muratori, A. Salvatori, A. Giannini, and M. Carini Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype Endocrinology 141 2000 3172 3182
16. L.M. Shaw, I. Rabinovitz, H.H. Wang, A. Toker, and A.M. Mercurio Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion Cell 91 1997 949 960
17. L. Bonaccorsi, M. Muratori, V. Carloni, S. Zecchi, L. Formigli, and G. Forti Androgen receptor and prostate cancer invasion Int J Androl 26 2003 21 25
18. B. Cinar, K.S. Koeneman, M. Edlund, G.S. Prins, H.E. Zhau, and L.W. Chung Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line Cancer Res 61 2001 7310 7317
19. L. Bonaccorsi, V. Carloni, M. Muratori, L. Formigli, S. Zecchi, and G. Forti EGF receptor (EGFR) signalling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) Int J Cancer 112 2004 78 86
20. L. Bonaccorsi, M. Muratori, V. Carloni, S. Marchiani, L. Formigli, and G. Forti The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells Steroids 69 2004 549 552
21. L. Bonaccorsi, S. Marchiani, M. Muratori, V. Carloni, G. Forti, and E. Baldi Signalling mechanisms that mediate invasion in prostate cancer cells Ann N Y Acad Sci 1028 2004 283 288
22. K.E. Longva, F.D. Blystad, E. Stang, A.M. Larsen, L.E. Johannessen, and I.H. Madshus Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies J Cell Biol 156 2002 843 854
23. M.H. Schmidt, F.B. Furnari, W.K. Cavenee, and O. Bogler Epidermal growth factor receptor signalling intensity determines intracellular protein interactions, ubiquitination, and internalization Proc Natl Acad Sci USA 100 2003 6505 6510
24. C. Mineo, G.N. Gill, and R.G. Anderson Regulated migration of epidermal growth factor receptor from caveolae J Biol Chem 274 1999 30636 30643
25. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in TRAMP mice. J Biol Chem 2005 [Epub ahead of print].
26. M.L. Lu, M.C. Schneider, Y. Zheng, X. Zhang, and J.P. Richie Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation J Biol Chem 276 2001 13442 13451
27. Puri C, Tosoni D, Comai R, Rabellino A, Segat D, Caneva F, et al. Relationships between EGFR signalling-competent and endocytosis-competent membrane microdomains. Mol Biol Cell 2005 [Epub ahead of print].
28. C. Le Roy, and J.L. Wrana Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling Nat Rev Mol Cell Biol 6 2005 112 126
29. A. Migliaccio, G. Castoria, M. Di Domenico, A. de Falco, A. Bilancio, and M. Lombardi Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation EMBO J 19 2000 5406 5417
30. T. Simoncini, A. Hafezi-Moghadam, D.P. Brazil, K. Ley, W.W. Chin, and J.K. Liao Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase Nature 407 2000 538 541
31. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signalling and Vitamin D receptor action in prostate cancer cells. Prostate 2005 [Epub ahead of print].
32. L.V. Stewart, and N.L. Weigel Vitamin D and prostate cancer Exp Biol Med 229 2004 277 284
33. V.M. Hayes, G. Severi, E.J. Padilla, S.A. Eggleton, M.C. Southey, and R.L. Sutherland Genetic variants in the Vitamin D receptor gene and prostate cancer risk Cancer Epidemiol Biomarkers Prev 14 2005 997 999
34. Y.R. Lou, S. Qiao, R. Talonpoika, H. Syvala, and P. Tuohimaa The role of Vitamin D3 metabolism in prostate cancer J Steroid Biochem Mol Biol 92 2004 317 325
35. C. Crescioli, M. Maggi, M. Luconi, G.B. Vannelli, R. Salerno, and A.A. Sinisi Vitamin D3 analogue inhibits keratinocyte growth factor signalling and induces apoptosis in human prostate cancer cells Prostate 50 2002 15 26
36. C. Crescioli, P. Ferruzzi, A. Caporali, R. Mancina, A. Comerci, and M. Muratori Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog Endocrinology 144 2003 3046 3057
37. D.M. Peehl, and D. Feldman Interaction of nuclear receptor ligands with the Vitamin D signalling pathway in prostate cancer J Steroid Biochem Mol Biol 92 2004 307 315
38. A.W. Norman, W.H. Okamura, J.E. Bishop, and H.L. Henry Update on biological actions of 1alpha,25(OH)2-Vitamin D3 (rapid effects) and 24R,25(OH)2-Vitamin D3 Mol Cell Endocrinol 197 2002 1 13
39. V. Sung, and D. Feldman 1,25-DihidroxyVitamin D3 decreases human prostate cancer cell adhesion and migration Mol Cell Endocrinol 164 2000 133 143
40. C. Crescioli, P. Ferruzzi, A. Caporali, M. Scaltriti, S. Bettuzzi, and R. Mancina Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia Eur J Endocrinol 150 2004 591 603
41. R. Berger, P.G. Febbo, P.K. Majumder, J.J. Zhao, S. Mukherjee, and S. Signoretti Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells Cancer Res 64 2004 8867 8875
42. H. Peterziel, S. Mink, A. Schonert, M. Becker, H. Klocker, and A.C. Cato Rapid signalling by androgen receptor in prostate cancer cells Oncogene 18 1999 6322 6329
43. A. Evangelou, M. Letarte, A. Marks, and T.J. Brown Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor Endocrinology 143 2002 3897 3904
44. C.N. Papandreou, B. Usmani, Y. Geng, T. Bogenrieder, R. Freeman, and S. Wilk Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression Nat Med 4 1998 50 57
45. E.J. Manos, M.L. Kim, J. Kassis, P.Y. Chang, A. Wells, and D.A. Jones Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion Oncogene 20 2001 2781 2790
46. V. Srikantan, M. Valladares, J.S. Rhim, J.W. Moul, and S. Srivastava HEPSIN inhibits cell growth/invasion in prostate cancer cells Cancer Res 62 2002 6812 6816
47. X. Liao, J.B. Thrasher, J. Pelling, J. Holzbeierlein, Q.X. Sang, and B. Li Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer Endocrinology 144 2003 1656 1663
48. A. Hatzoglou, M. Kampa, C. Kogia, I. Charalampopoulos, P.A. Theodoropoulos, and P. Anezinis Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo J Clin Endocrinol Metab 90 2005 893 903
49. V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, and A. Maggi The androgen derivative 5α-androstane-3β, 17β-diol inhibits prostate cancer cell migration through activation of estrogen receptor β subtype Cancer Res 65 2005 5445 5453
50. JE. Osborne, and P.E. Hutchinson Vitamin D and systemic cancer is this relevant to malignant melanoma British J Dermatol 147 2002 197 213
51. C. Crescioli, P. Ferruzzi, A. Caporali, M. Scaltriti, S. Bettuzzi, and R. Mancina Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia Eur J Endocrinol 150 2004 591 603